ライフサイエンスコーパス: growth restriction

1 placentation (preeclampsia and intrauterine growth restriction).

2 t of its dehydrogenase activity, even during growth restriction.

3 cental growth factor levels and intrauterine growth restriction.

4 proliferation, including fetal and postnatal growth restriction.

5 ous abortion, preeclampsia, and intrauterine growth restriction.

6 s, hearing and vision loss, and intrauterine growth restriction.

7 from maternal blood and contributes to fetal growth restriction.

8 obactin critical for overcoming SCN-mediated growth restriction.

9 nerational family with four members who have growth restriction.

10 was preceded by preeclampsia or intrauterine growth restriction.

11 ce or absence of ultrasonic markers of fetal growth restriction.

12 ger delivery in mothers of babies with fetal growth restriction.

13 status who were at low risk of intrauterine growth restriction.

14 status who were at low risk of intrauterine growth restriction.

15 icated with intervillositis, can cause fetal growth restriction.

16 play a role in the pathophysiology of fetal growth restriction.

17 eral are of pathological relevance for fetal growth restriction.

18 worldwide and is often complicated by fetal growth restriction.

19 ling responses, and contributes to bacterial growth restriction.

20 ria, and edema) and, in some patients, fetal growth restriction.

21 y disorders including preeclampsia and fetal growth restriction.

22 ulation is associated with fetal hypoxia and growth restriction.

23 o analyze the role of T6P/SnRK1 in relief of growth restriction.

24 ike systemic acquired resistance or pathogen growth restriction.

25 major birth defects, preterm birth, or fetal growth restriction.

26 PCE area, was associated with LBW and fetal growth restriction.

27 ng late miscarriage, preeclampsia, and fetal growth restriction.

28 t for early preterm birth and possibly fetal growth restriction.

29 preeclampsia, placental abruption, or fetal growth restriction.

30 ssociated with maternal infections and fetal growth restriction.

31 structural and functional abnormalities and growth restriction.

32 ond to mitogenic stimuli can cause embryonic growth restriction.

33 cytokines that have been implicated in fetal growth restriction.

34 amma levels at birth may be related to fetal growth restriction.

35 l inflammation and was associated with fetal growth restriction.

36 ed by significant intrauterine and postnatal growth restriction.

37 ow birth weight infants experience postnatal growth restriction.

38 Igf2 alone results in proportional placental growth restriction.

39 pre-eclampsia or eclampsia, and intrauterine growth restriction.

40 eeclampsia and fetal indication/intrauterine growth restriction.

41 lf of pregnancy and is associated with fetal growth restriction.

42 ly prevented the high altitude-induced fetal growth restriction.

43 have not generally reduced preterm birth or growth restriction.

44 the relative risk for pre-term delivery and growth restriction.

45 weight and increase the risk of intrauterine growth restriction.

46 ng predictor of both preterm birth and fetal growth restriction.

47 tions have failed to reduce preterm birth or growth restriction.

48 as identified in humans with early postnatal growth restriction.

49 l conditions, including stillbirth and fetal growth restriction.

50 o acid transporter activity and causes fetal growth restriction.

51 sulted in reduced placental weight and fetal growth restriction.

52 ral malformations and linked to intrauterine growth restriction.

53 ations, uteroplacental dysfunction, or fetal growth restriction.

54 d preterm newborns without evidence of fetal growth restriction.

55 response to hypoxia, a major cause of fetal growth restriction.

56 thological process of interest, intrauterine growth restriction.

57 impaired spiral artery remodeling with fetal growth restriction.

58 en, especially those at higher risk of fetal growth restriction.

59 utero-placental perfusion, hypertension and growth restriction.

60 l age and those with pathologic intrauterine growth restriction.

61 onal hypoxia such as pre-eclampsia and fetal growth restriction.

62 ation; 1.16, 1.01-1.34; I(2)=64%), and fetal growth restriction (1.26, 1.20-1.33; I(2)=1%).

63 An atmosphere of 13% oxygen induced fetal growth restriction (1182 +/- 9 mg, n = 90 vs. 1044 +/- 1

64 ence (5%), and fetal indication/intrauterine growth restriction (3%).

65 6 [22%] vs 2/71 [3%]; p=0.002), intrauterine growth restriction (34/37 [92%] vs 34/70 [48%]; p<0.0001

66 ntrast, paternally transmitted hIC1 leads to growth restriction, abnormal hIC1 methylation, and loss

67 ith pregnancies characterized by fetal loss, growth restriction, abnormal placental development, and

68 a preterm birth or secondary to intrauterine growth restriction, account for much of the increased mo

69 disparities exist in both preterm birth and growth restriction among different population groups.

70 els indicate that (a) therapies which induce growth restriction among metastases but do not prevent i

71 HA pregnancy led to chronic fetal hypoxia, growth restriction and altered cardiovascular function.

72 High-altitude hypoxia causes intrauterine growth restriction and cardiovascular programming.

73 incident CHF, atrial arrhythmias, and fetal growth restriction and complex CHD was associated with v

74 weaning induces a linear correlation between growth restriction and DNA methylation at ribosomal DNA

75 Stillbirth is associated with both growth restriction and excessive fetal growth.

76 D at GD14 and GD18 in association with fetal growth restriction and higher blood pressure.

77 y be due to conditions associated with fetal growth restriction and iatrogenic preterm birth.

78 ant dams during early pregnancy led to fetal growth restriction and infection of the fetal brain in W

79 o abortion, premature delivery, intrauterine growth restriction and low birth weight.

80 ating fetal outcomes, including intrauterine growth restriction and microcephaly.

81 Here we show that both fetal growth restriction and over-growth are associated with g

82 Here, we developed a mouse model of fetal-growth restriction and placental insufficiency that is i

83 nancy complications, including intra-uterine growth restriction and pre-eclampsia.

84 placental perfusion, leading to intrauterine growth restriction and preeclampsia, is the failure of i

85 ntal hypoxia is causally implicated in fetal growth restriction and preeclampsia, with both occurring

86 on and oxidative stress; and in the fetus as growth restriction and progressive hypoxemia.

87 nd metabolic pathways required for bacillary growth restriction and reactivation.

88 occurred in other pregnancy disorders (fetal growth restriction and recurrent miscarriage), indicatin

89 uish placental dysfunction from intrauterine growth restriction and reveal a role for the placenta in

90 dition of the placenta associated with fetal growth restriction and stillbirth.

91 is an important mediator in fetal death and growth restriction and that statins may be a good treatm

92 is a significant mechanism underlying fetal growth restriction and the programming of adverse health

93 have suggested an association between fetal growth restriction and the risk of spontaneous preterm b

94 egnancy outcomes in severe early-onset fetal growth restriction and therefore it should not be prescr

95 of placentas from newborns with intrauterine growth restriction and underlying congenital HCMV infect

96 a role in the investigation of intrauterine growth restriction and unexplained stillbirth.

97 othesis that shared factors cause both fetal growth restriction and urogenital anomalies was supporte

98 tions are associated with proportional fetal growth restriction and with an increased risk of preterm

99 tas from pregnancies with severe early-onset growth-restriction and preeclampsia displaying abnormal

100 us and is associated with fetal death, fetal growth restriction, and a spectrum of central nervous sy

101 low birth weight (LBW), preterm birth, fetal growth restriction, and birth defects among births to wo

102 Preterm birth, intrauterine growth restriction, and delivery-related hypoxia have be

103 t-for-gestational-age, an indicator of fetal growth restriction, and furthermore the authors observed

104 mutant embryos exhibit gene dosage-dependent growth restriction, and homozygous mutants exhibit upper

105 includes babies born preterm and with fetal growth restriction, and not all these infants have a bir

106 ptoms that resolve soon after birth, such as growth restriction, and permanent disabilities, includin

107 tetric outcomes such as pre-eclampsia, fetal growth restriction, and preterm birth.

108 transmission, pup viral loads, intrauterine growth restriction, and pup mortality comparable to that

109 rated increased amniotic fluid, intrauterine growth restriction, and reduced litter size with postnat

110 ns of pregnancy, such as preeclampsia, fetal growth restriction, and stillbirth.

111 y complications, such as preeclampsia, fetal growth restriction, and stillbirth.

112 Increased morbidity and fetal growth restriction are reported in uninfected children b

113 We defined fetal growth restriction as a combination of estimated fetal w

114 ed the prevailing hypotheses regarding fetal growth restriction as a risk factor for urogenital anoma

115 s understanding and interpretations of fetal growth restriction as represented by small for gestation

116 uding: (i) neurotransmitter deficiencies and growth restriction associated with branched-chain amino

117 Fetal growth restriction associates with increased risk of adu

118 bryos and placentas exhibit strain-dependent growth restriction at 15.5 days post-coitus while Egfr(W

119 hfq deletion caused severe growth restriction at 37 degrees C in Y. pestis but not

120 Hypoxia-related fetal growth restriction becomes apparent between 25 and 29 wk

121 s population, all children were experiencing growth restriction but differences in magnitude were inf

122 Both models lead to intrauterine growth restriction but dissociate between a situation wh

123 were each characterized by worsening linear growth restriction but varied in the timing and severity

124 evels in pregnancy are associated with fetal growth restriction, but the underlying mechanisms are po

125 itamin D deficiency has been linked to fetal growth restriction, but the underlying mechanisms are un

126 acco exposure has been associated with fetal growth restriction, but uncertainty remains about critic

127 ase that counteracts intracellular bacterial growth restriction by phytate.

128 role during MV infection but that the virus growth restriction by PKR is not dependent upon the indu

129 Severe early-onset fetal growth restriction can lead to a range of adverse outcom

130 that metastases must undergo to escape from growth restriction, cannot be extracted from relapse dat

131 Extrauterine growth restriction, catch-up growth, altered adiposity,

132 EL mice and in another model of intrauterine growth restriction caused by ectopic expression of uncou

133 strain-dependent differences in intrauterine growth restriction caused by reduced EGFR activity.

134 f rat MOv18 IgE demonstrated superior tumour growth restriction compared with rat MOv18 IgG (tumour o

135 the mouse Mtrr gene results in intrauterine growth restriction, developmental delay, and congenital

136 Fetal outcomes included growth restriction, distress, and death.

137 We generated a new model of intrauterine growth restriction due to fatty acid synthase (FAS) hapl

138 The patients exhibited growth restriction, dysmorphic features, and development

139 umption led to placental inefficiency, fetal growth restriction, elevated fetal serum glucose and tri

140 ues characterize 5 individuals who exhibited growth restriction, facial deformities, and a history of

141 he alloy compositions are converted to their growth restriction factors (Q) and that increasing Q had

142 irment, behavioral alterations, intrauterine growth restriction, feeding problems, and various congen

143 otrophoblasts, leading to intrauterine fetal growth restriction, fetal liver hypocellularity, and dem

144 e availability causes diseases such as fetal growth restriction, fetal malformations and cancer.

145 lability causes human diseases such as fetal growth restriction, fetal malformations and cancer.

146 Fetal growth restriction (FGR) affects 5% to 10% of newborns a

147 Fetal growth restriction (FGR) affects around 5% of pregnancie

148 and choline status resulted in severe fetal growth restriction (FGR) and impaired fertility in litte

149 Fetal growth restriction (FGR) and preeclampsia (PE) are often

150 posure to disinfection by-products and fetal growth restriction (FGR) and preterm birth in the PELAGI

151 motherhood and short birth intervals, fetal growth restriction (FGR) and preterm birth, child nutrit

152 maternal age (AMA) are susceptible to fetal growth restriction (FGR) and stillbirth.

153 Preeclampsia (PE) and fetal growth restriction (FGR) are serious complications of pr

154 lacental vessel networks in normal and fetal growth restriction (FGR) complicated pregnancies.

155 Fetal growth restriction (FGR) is associated with global adver

156 However, placentas from fetal growth restriction (FGR) pregnancies are characterized b

157 Fetal growth restriction (FGR) results from placental insuffic

158 most common and preventable causes of fetal growth restriction (FGR), a condition in which a fetus i

159 l pregnancies and those complicated by fetal growth restriction (FGR).

160 jor cause of antepartum stillbirth and fetal growth restriction (FGR).

161 ive aetiologies in the pathogenesis of fetal growth restriction (FGR); however, the regulating sites

162 n relievers in the clinic, can surmount axon growth restrictions from myelin and proteoglycans by pot

163 syndromic coronal craniosynostosis to severe growth restriction, fulfilling diagnostic criteria for M

164 hich are linked with these exposures include growth restriction, functional abnormalities, structural

165 Intra-uterine growth restriction has also been reported in various ani

166 F1 or IGF1R cause intrauterine and postnatal growth restriction; however, data on mutations in IGF2,

167 eeks of gestation who had very preterm fetal growth restriction (ie, low abdominal circumference [<10

168 rvival of neural progenitors and reduces the growth restriction imposed by Aspm deletion.

169 The severe growth restriction in affected family members suggests t

170 Placental sO2 was lower in fetal growth restriction in an angiotensin-converting enzyme 2

171 OM ARABIDOPSIS THALIANA6 expression and that growth restriction in BOP1/2 gain-of-function plants req

172 is supported by Hmox1 and ameliorates fetal-growth restriction in Hmox1 deficiency.

173 ous embryos model EGFR-mediated intrauterine growth restriction in humans.

174 transcript alone (Igf2P0(+/-)) lead to fetal growth restriction in mice.

175 is phenotypic difference, the L. pneumophila growth restriction in MOLF/Ei macrophages was mapped to

176 (OR, 31.8; 95% CI, 4.3-236.3) CHD, for fetal growth restriction in noncomplex (OR, 1.6; 95% CI, 1.3-2

177 NA replication products in vitro and display growth restriction in some cultured cells.

178 y; Sildenafil does not protect against fetal growth restriction in the chick embryo, supporting the i

179 placental growth restriction precedes fetal growth restriction in the Igf2P0(+/-) mouse.

180 corresponding to the distinctive patterns of growth restriction in these mutants leading to compacted

181 distinctive phenotypes of IFN antagonism and growth restriction in wild-type MEFs to NSP1.

182 Sequelae of fetal growth restriction include metabolic disease as well as

183 Markers of fetal growth restriction included biometric ratios, utero-plac

184 -borne virus recently linked to intrauterine growth restriction including abnormal fetal brain develo

185 found that ZIKV infection leads to postnatal growth restriction including microcephaly.

186 KV(BR) infects fetuses, causing intrauterine growth restriction, including signs of microcephaly, in

187 he authors investigated whether intrauterine growth restriction (indexed by birth weight and length)

188 glucose homeostasis and is altered by fetal growth restriction induced by maternal undernutrition.

189 associated with amniotic band formation and growth restriction induced in rats by amniocentesis, as

190 ns of the disease included mild intrauterine growth restriction, infantile hypotonia, and irritabilit

191 Intrauterine growth restriction is a leading cause of perinatal morbi

192 Fetal growth restriction is a major determinant of adverse per

193 a sexually dimorphic response; intrauterine growth restriction is associated with substantially grea

194 dNK inhibition, the risk of pre-eclampsia or growth restriction is increased.

195 Intrauterine growth restriction (IUGR) affects up to 10% of pregnanci

196 l and postnatal factors such as intrauterine growth restriction (IUGR) and high-fat (HF) diet contrib

197 al nutrient restriction induces intrauterine growth restriction (IUGR) and leads to heightened cardio

198 Pregnancy loss and intrauterine growth restriction (IUGR) are serious pregnancy complica

199 Intrauterine growth restriction (IUGR) confers heritable alterations

200 Intrauterine growth restriction (IUGR) decreases serum IGF-1 levels.

201 Intrauterine growth restriction (IUGR) decreases serum insulin growth

202 Placental insufficiency-induced intrauterine growth restriction (IUGR) fetuses have chronic hypoxaemi

203 s such as preeclampsia (PE) and intrauterine growth restriction (IUGR) in 20% of patients.

204 KEY POINTS: Intrauterine growth restriction (IUGR) increases offspring risk of ch

205 Intrauterine growth restriction (IUGR) increases susceptibility to ag

206 Intrauterine growth restriction (IUGR) increases the risk for metabol

207 Intrauterine growth restriction (IUGR) is a common complication of pr

208 Intrauterine growth restriction (IUGR) is a failure to achieve the gr

209 Intrauterine growth restriction (IUGR) is a pathology of pregnancy th

210 caloric intake superimposed on intrauterine growth restriction (IUGR) is associated with adult-onset

211 Intrauterine growth restriction (IUGR) is associated with an increase

212 Intrauterine fetal growth restriction (IUGR) is often associated with compr

213 Intrauterine growth restriction (IUGR) leads to development of type 2

214 Placental insufficiency and intrauterine growth restriction (IUGR) of the fetus affects approxima

215 We hypothesized that intrauterine growth restriction (IUGR) offspring hearts would show im

216 e also evaluated the effects of intrauterine growth restriction (IUGR) on carotenoid status in term n

217 was to determine the impact of intrauterine growth restriction (IUGR) on pancreatic vascularity and

218 l muscle mass in the fetus with intrauterine growth restriction (IUGR) persists into adulthood and ma

219 Intrauterine growth restriction (IUGR) reduces skeletal muscle mass i

220 KEY POINTS: Rodent models of intrauterine growth restriction (IUGR) successfully identify mechanis

221 Rodent models of intrauterine growth restriction (IUGR) successfully identify mechanis

222 TS: Adults who were affected by intrauterine growth restriction (IUGR) suffer from reductions in musc

223 ndrome that is characterized by intrauterine growth restriction (IUGR) with gonadal, adrenal, and bon

224 estriction (NR) culminating in intra-uterine growth restriction (IUGR) with postnatal catch up growth

225 to decreased beta cell growth, intrauterine growth restriction (IUGR), and impaired placental develo

226 al nutrient restriction induces intrauterine growth restriction (IUGR), increasing later life chronic

227 rnal nutrient reduction induces intrauterine growth restriction (IUGR), increasing risks of chronic d

228 olic syndrome (MetS), following intrauterine growth restriction (IUGR), is epigenetically heritable.

229 ion process are associated with Intrauterine Growth Restriction (IUGR), Preeclampsia (PE) and High El

230 in mid-gestation lethality and intrauterine growth restriction (IUGR).

231 fection is also associated with intrauterine growth restriction (IUGR).

232 B), low birth weight (LBW), and intrauterine growth restriction (IUGR).

233 ed with fetuses who suffer from intrauterine growth restriction (IUGR).

234 hown to prevent preeclampsia or intrauterine growth restriction (IUGR).

235 osis using two mouse models for intrauterine growth restriction (IUGR): maternal protein restriction

236 les had offspring with third-trimester fetal growth restriction, leading to a smaller head circumfere

237 characterized by short stature, intrauterine growth restriction, lipoatrophy and a facial gestalt inv

238 r the fetus and newborn include intrauterine growth restriction, low birth weight, and stillbirth.

239 Epidemiological data suggest that fetal growth restriction, maternal factors such as smoking, al

240 There is some evidence that this postnatal growth restriction may have long-lasting effects, and co

241 IMAGe syndrome (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypop

242 ssive disorder characterized by severe fetal growth restriction, microcephaly, a distinct facial appe

243 Screening procedures for fetal growth restriction need to identify small babies and the

244 Postnatal growth restriction occurred in pups in UPI/RA, but not i

245 However, in the Igf2null(+/-) this growth restriction occurs concurrently in gestation with

246 However, growth restriction of bacteria lacking PlcA, PlcB, and A

247 tophagic processes responsible for bacterial growth restriction of Listeria monocytogenesL.

248 treated patients triggered acidification and growth restriction of M. tuberculosis in macrophages.

249 Unexplained intrauterine growth restriction of the fetus (IUGR) results from impa

250 We then tested 39 patients with severe growth restriction of unknown etiology, and found hypome

251 Growth restriction of Yersinia pestis in the absence of

252 ive peptides significantly overcomes neurite growth restrictions of CSPGs in neuronal cultures.

253 luated the effect of malaria on intrauterine growth restriction on the basis of the fetal growth rate

254 after implantation, along with intrauterine growth restriction or embryonic death.

255 confounding factors, including intrauterine growth restriction or factors related to the cause of in

256 had used LMWH); and 11 cases of intrauterine growth restriction or placental insufficiency (5 women h

257 utcomes (N = 29) and those with intrauterine growth restriction or preeclampsia (N = 12).

258 the effect of potential confounders such as growth restriction or prematurity remain to be elucidate

259 paired placental function, either with fetal growth restriction or preterm labour, or both.

260 re, medically indicated preterm birth, fetal-growth restriction, or perinatal death.

261 nt syndrome, intrauterine fetal death, fetal growth restriction, or placental abruption who had been

262 tion without congenital malformations, fetal growth restriction, or severe postnatal morbidity.

263 ransport are decreased in human intrauterine growth restriction our data are consistent with the poss

264 In contrast, postnatal NR with growth restriction (PNGR) superimposed on IUGR (IPGR) pr

265 eight (<2500 g), pre-term birth (<37 weeks), growth restriction, pre-eclampsia, miscarriage and/or st

266 ental growth restriction, whereas, placental growth restriction precedes fetal growth restriction in

267 ic fluid and/or newborn saliva, intrauterine growth restriction, preterm deliveries, and controls.

268 gnancy complications, including intrauterine growth restriction, preterm delivery, and stillbirth.

269 mice died perinatally associated with fetal growth restriction, reduced hepatic glycogen stores, and

270 ment of pregnancies at risk for intrauterine growth restriction relies on accurate identification and

271 rrelation to recurrent miscarriage and fetal growth restriction, revealing the common mechanism under

272 I, 0.62 to 0.95]), 1% to 5% for intrauterine growth restriction (RR, 0.80 [CI, 0.65 to 0.99]), and 2%

273 lood flow and relative protection from fetal growth restriction seen in altitude-adapted Andean popul

274 t Nations population and causes intrauterine growth restriction, severe microcephaly, craniofacial an

275 Measures of growth restriction showed weak and inconsistent associat

276 ection in pregnant women causes intrauterine growth restriction, spontaneous abortion, and microcepha

277 ations, including preeclampsia, intrauterine growth restriction, spontaneous abortion, preterm birth,

278 rnutrition in the aggregate--including fetal growth restriction, stunting, wasting, and deficiencies

279 ed late gestation fetuses display asymmetric growth restriction, suggestive of a redistribution of nu

280 33S(;)P168S] variant in ROP and intrauterine growth restriction suggests that it also may be a marker

281 e the preterm birth rate and higher rates of growth restriction than do most other women.

282 cy complication associated with intrauterine growth restriction that may influence respiratory outcom

283 We used a mouse model of fetal growth restriction, the placental-specific Igf2 knockout

284 placental malaria per se, might cause fetal growth restriction, through impaired transplacental gluc

285 an expanded adipose tissue results from cell growth restriction to prevent cell necrosis.

286 days' gestation and severe early-onset fetal growth restriction to receive either sildenafil 25 mg th

287 Tumor growth restriction was associated with vascular apoptosi

288 d the multiplication of M. tuberculosis, and growth restriction was dependent on acidification of the

289 s with human recurrent miscarriage and fetal growth restriction, we identified tissue factor (TF) as

290 gh-potency steroids have been shown to cause growth restriction when used during pregnancy.

291 urs concurrently in gestation with placental growth restriction, whereas, placental growth restrictio

292 Maternal undernutrition contributes to fetal growth restriction, which increases the risk of neonatal

293 tal pathologies associated with intrauterine growth restriction, which is a significant cause of infa

294 of sizeable micrometastases that escape from growth restriction with a half-life exceeding 12 years.

295 at 10 years postresection, when they escape growth restriction with a half-life of <69 years and are

296 6 dangerous micrometastases that escape from growth restriction with a half-life of at least 12 years

297 al differentiation and senescence-associated growth restriction with increased levels of phosphorylat

298 elin-derived inhibitors contribute to axonal growth restriction, with ephrinB3 being a developmentall

299 lies, suggesting an effect of relative fetal growth restriction within families.

300 le, maternal smoking (Z) is a cause of fetal growth restriction (X), which subsequently affects prete